...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of pain & palliative care pharmacotherapy >A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders.
【24h】

A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders.

机译：口服锌治疗与化疗有关的味觉和嗅觉障碍的随机，安慰剂对照试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abnormalities in taste and smell are commonly reported in patients receiving chemotherapy and may hinder appetite, dietary intake, nutritional well-being, and quality of life. Oral zinc has been used to treat taste and smell abnormalities in several altered physiologic states, including renal failure, liver disease, head trauma, and pregnancy, with varying results. The authors conducted a double-blinded, placebo-controlled randomized clinic trial over 3 months. Eligible patients were those taking chemotherapy that had alterations in taste and/or smell. The measurement of the primary end point, improvement in altered taste and smell, was made using a 0-100 scale (100 describing no loss or distortion in taste and smell, and 0 describing the worst distortion or loss of taste and smell). Twenty-nine subjects were enrolled in each treatment group, of whom 31 were white, 26 African American, and 1 Native American. Forty-one patients were female. A wide range of cancer types was represented, with breast the most common (21 patients). The zinc dose was 220 mg orally twice daily (equivalent of 50 mg elemental zinc twice daily). There was no statistically significant improvement in loss or distortion of taste or smell with the addition of zinc. There was a trend toward improvement over time in all groups, except in the zinc group where there was a nonsignificant worsening in loss of smell over time. Zinc at standard doses did not provide significant benefit to taste or smell in patients receiving chemotherapy.
机译：据报道，接受化疗的患者的味觉和嗅觉异常，可能会影响食欲，饮食摄入，营养状况和生活质量。口服锌已被用于治疗几种生理状态改变的味觉和嗅觉异常，包括肾衰竭，肝病，头部外伤和妊娠，结果各异。作者进行了为期3个月的双盲，安慰剂对照随机临床试验。符合条件的患者是接受化学疗法的患者，其口味和/或气味有所改变。主要终点的测量是改变味道和气味的改善，使用0-100刻度进行测量（100描述没有味道和气味的损失或变形，而0描述最糟糕的味道和气味的变形或损失）。每个治疗组招募了29名受试者，其中31名是白人，26名非裔美国人和1名美国原住民。 41名患者是女性。代表了多种癌症类型，最常见的是乳腺癌（21例患者）。锌的剂量为每天两次口服220 mg（相当于每天两次的50 mg元素锌）。添加锌后，味觉或气味的丧失或失真没有统计学上的显着改善。除锌组外，所有组的气味都随着时间的流逝而逐渐改善，锌组的气味流失随时间的推移没有明显的恶化。标准剂量的锌对接受化疗的患者的味觉或嗅觉没有明显的帮助。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号